BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 35928454)

  • 1. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
    Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
    J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
    Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
    Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
    Tan Y; Lu L; Liang X; Chen Y
    World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
    Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
    J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
    Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
    Front Genet; 2022; 13():951311. PubMed ID: 36406130
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma.
    Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G
    Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
    Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis.
    Huang H; Shi Z; Li Y; Zhu G; Chen C; Zhang Z; Shi R; Su L; Cao P; Pan Z; Zhang H; Liu M; Liu H; Chen J
    Front Oncol; 2022; 12():850943. PubMed ID: 35311148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
    Sun D; Zhang C
    Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
    Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
    Front Surg; 2022; 9():860806. PubMed ID: 35937602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Pyroptosis-Related Gene Signature for Predicting the Immune Status and Prognosis in Lung Adenocarcinoma.
    Gong Z; Li Q; Yang J; Zhang P; Sun W; Ren Q; Tang J; Wang W; Gong H; Li J
    Front Bioeng Biotechnol; 2022; 10():852734. PubMed ID: 35646872
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.